LV13033B - Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplantant rejection - Google Patents

Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplantant rejection Download PDF

Info

Publication number
LV13033B
LV13033B LVP-03-25A LV030025A LV13033B LV 13033 B LV13033 B LV 13033B LV 030025 A LV030025 A LV 030025A LV 13033 B LV13033 B LV 13033B
Authority
LV
Latvia
Prior art keywords
methyl
ccr1 receptor
chloro
receptor antagonist
phenoxy
Prior art date
Application number
LVP-03-25A
Other languages
English (en)
Latvian (lv)
Inventor
Richard Horuk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of LV13033B publication Critical patent/LV13033B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-03-25A 2000-07-31 2003-02-28 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplantant rejection LV13033B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22205300P 2000-07-31 2000-07-31
US23128200P 2000-09-08 2000-09-08
US09/915,411 US6740636B2 (en) 2000-07-31 2001-07-25 Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection

Publications (1)

Publication Number Publication Date
LV13033B true LV13033B (en) 2004-02-20

Family

ID=27397025

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-03-25A LV13033B (en) 2000-07-31 2003-02-28 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplantant rejection

Country Status (28)

Country Link
US (1) US6740636B2 (xx)
EP (1) EP1305047B1 (xx)
JP (1) JP2004530630A (xx)
KR (1) KR20030048000A (xx)
CN (1) CN1655818A (xx)
AT (1) ATE330634T1 (xx)
AU (2) AU2001278073B2 (xx)
BG (1) BG107502A (xx)
BR (1) BR0113140A (xx)
CA (1) CA2417636A1 (xx)
CY (1) CY1105321T1 (xx)
DE (1) DE60120986T2 (xx)
DK (1) DK1305047T3 (xx)
EE (1) EE200300047A (xx)
ES (1) ES2261447T3 (xx)
HR (1) HRP20030121A2 (xx)
HU (1) HUP0300686A3 (xx)
IL (1) IL153933A0 (xx)
LV (1) LV13033B (xx)
MX (1) MXPA03000836A (xx)
NO (1) NO20030475L (xx)
NZ (1) NZ523688A (xx)
PL (1) PL364521A1 (xx)
PT (1) PT1305047E (xx)
SI (1) SI21123A (xx)
SK (1) SK1222003A3 (xx)
WO (1) WO2002009762A2 (xx)
YU (1) YU6703A (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413846A (pt) * 2003-08-22 2006-10-24 Schering Aktiengellschaft derivados de piperazina inibidores de quimiocina e seu uso para tratar miocardite
US7917195B2 (en) 2004-03-05 2011-03-29 Lifesciences Solutions LLC Systems, methods and computer program products for heart monitoring
US10499828B2 (en) * 2004-03-05 2019-12-10 Lifescience Solutions, Llc System and method for heart monitoring
US8103065B2 (en) * 2006-01-05 2012-01-24 Lifescience Solutions Llc Assessment of medical conditions
US20110009758A1 (en) * 2009-07-10 2011-01-13 Lifescience Solutions Llc System and method for heart monitoring

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2282834C (en) 1997-02-26 2004-10-05 Pfizer Inc. Novel hexanoic acid derivatives
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AU2331999A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
AU2335699A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
BR9907655A (pt) 1998-02-05 2000-10-24 Pfizer Prod Inc Derivados de ácido di-hidróxi-hexanóico
EP1000626A1 (en) 1998-09-18 2000-05-17 Applied Research Systems ARS Holding N.V. Chemokine receptor antagonist and cyclosporin in combined therapy
WO2000044365A1 (en) 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methods for preventing graft rejection and ischemia-reperfusion injury

Also Published As

Publication number Publication date
EP1305047B1 (en) 2006-06-21
YU6703A (sh) 2006-05-25
AU7807301A (en) 2002-02-13
PL364521A1 (en) 2004-12-13
CA2417636A1 (en) 2002-02-07
BG107502A (en) 2003-07-31
KR20030048000A (ko) 2003-06-18
WO2002009762A3 (en) 2003-01-09
ES2261447T3 (es) 2006-11-16
MXPA03000836A (es) 2003-06-06
IL153933A0 (en) 2003-07-31
NZ523688A (en) 2005-04-29
NO20030475L (no) 2003-03-28
CN1655818A (zh) 2005-08-17
PT1305047E (pt) 2006-11-30
HRP20030121A2 (en) 2005-02-28
CY1105321T1 (el) 2010-03-03
ATE330634T1 (de) 2006-07-15
DE60120986T2 (de) 2006-11-23
AU2001278073B2 (en) 2005-06-30
US20020039997A1 (en) 2002-04-04
SK1222003A3 (en) 2003-09-11
SI21123A (sl) 2003-08-31
BR0113140A (pt) 2003-06-24
WO2002009762A2 (en) 2002-02-07
EP1305047A2 (en) 2003-05-02
HUP0300686A2 (hu) 2003-08-28
JP2004530630A (ja) 2004-10-07
HUP0300686A3 (en) 2005-03-29
DK1305047T3 (da) 2006-10-23
NO20030475D0 (no) 2003-01-30
US6740636B2 (en) 2004-05-25
EE200300047A (et) 2004-10-15
DE60120986D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
Kopp et al. Cellular and molecular mechanisms of cyclosporin nephrotoxicity.
Pothoulakis et al. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin.
Vergnolle et al. A role for proteinase-activated receptor–1 in inflammatory bowel diseases
US20080058252A1 (en) Use of C5A receptor antagonist in the treatment of fibrosis
Ouseph et al. Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat
AU2001278073B2 (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
US20040091477A1 (en) Immunosuppresive compositions
AU2001278073A1 (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
JP2006528208A (ja) コンプリメント5a受容体阻害剤を使用する出血ショックの処置
ZA200301642B (en) Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection.
US6812230B2 (en) Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
EP2063908B1 (en) Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
JP2004510694A (ja) 免疫抑制性組成物
LT5132B (lt) Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
Crawford et al. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds
AU2003215446B2 (en) Use of C5a receptor antagonist in the treatment of fibrosis
Garaci et al. Ultrastructural and functional changes of the mouse thymus following treatment with an antiserum specific for thymic epithelial cells
Thomson et al. Rejection, the Immune Response, and the Influence of Cyclosporin A
AU2007200012A1 (en) Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound